Search
Search Results
-
Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer
BackgroundTamoxifen (TAM) is recommended as the first-line strategy for men with estrogen receptor (ER)-positive early breast cancer who are...
-
Development and psychometric evaluation of the adjuvant endocrine therapy beliefs scale for breast cancer survivors
PurposeAdjuvant endocrine therapy has a vital role in reducing breast cancer mortality. The beliefs in adjuvant endocrine therapy is a very important...
-
Develo** questions to assess and measure patients’ perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
This mixed method study developed multiple question types to understand and measure women’s perceived benefit from adjuvant endocrine therapy. We...
-
Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer
PurposeMammography screening has increased the detection of subcentimeter breast cancers. The prognosis for estrogen receptor (ER)-positive and human...
-
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis
PurposeOptimal extended adjuvant endocrine therapy (ET) duration and strategy for hormone receptor-positive (HR +) early breast cancer remain...
-
Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer
PurposeWeight gain after breast cancer poses health risks. We aimed to identify factors associated with weight gain during adjuvant endocrine therapy...
-
Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women
BackgroundHigh rates of discontinuation undermine the effectiveness of adjuvant endocrine therapy (AET) among hormone-receptive breast cancer...
-
Factors associated with worsening sexual function during adjuvant endocrine therapy in a prospective clinic-based cohort of women with early-stage breast cancer
PurposeSexual function problems are common but under-reported among women receiving adjuvant endocrine therapy for breast cancer. Worsening scores on...
-
A randomized trial of the impact of symptom monitoring using an electronic patient-reported outcome app on health-related quality of life in postmenopausal breast cancer patients receiving adjuvant endocrine therapy
BackgroundElectronic patient-reported outcomes (ePRO) monitoring is a useful communication tool for cancer patients and healthcare providers. In this...
-
Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer
PurposeSide effects are the main reason for discontinuation of adjuvant endocrine therapy in older adults. The aim of this study was to examine...
-
Concurrent factors associated with adherence to adjuvant endocrine therapy among women with non-metastatic breast cancer
PurposeAdjuvant endocrine therapy (AET) reduces breast cancer morbidity and mortality, yet women often report suboptimal adherence. Though correlates...
-
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
PurposeNeoadjuvant endocrine therapy (NET) is a treatment option for estrogen receptor-positive (ER+) postmenopausal early breast cancer (EBC). This...
-
Medication delivery factors and adjuvant endocrine therapy adherence in breast cancer
PurposeOver 50% of breast cancer patients prescribed a 5-year course of daily oral adjuvant endocrine therapy (ET) are nonadherent. We investigated...
-
Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Eli Lilly) of abemaciclib (Verzenios) to submit evidence for...
-
Factors influencing the first and the fifth years adherence to adjuvant endocrine therapy in breast cancer patients in a low income country
PurposeBreast cancer is the leading cause of cancer death in Brazil and in many countries around the world. In order to minimize the risk of...
-
Factors influencing the initiation of adjuvant endocrine therapy in patients with estrogen receptor-positive ductal carcinoma in situ: a single institution experience
PurposeThis study evaluates whether race, socioeconomic status, insurance type, oncological provider type, and prior cancer treatment are associated...
-
Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women
PurposeOral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and...
-
-
Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer
Background and ObjectiveAlthough improving adherence to adjuvant endocrine therapies (AETs) is critical to ensure better patient outcomes, the...
-
Hobson’s choice or a horned dilemma: a grounded theory on adherence to adjuvant endocrine therapy verified with breast cancer survivors
PurposeA literature review and meta-synthesis of qualitative research had enabled us to develop a grounded theory explaining the difficulties breast...
